Advanced assessment of the physicochemical characteristics of Remicade® and Inflectra® by sensitive LC/MS techniques

mAbs

Volumn 8, Issue 6, 2016, Pages 1021-1034

  Fang, Jing ^a   Doneanu, Catalin ^a   Alley, William R ^a   Yu, Ying Qing ^a   Beck, Alain ^b   Chen, Weibin ^a  

^a WATERS CORPORATION   (United States)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

2D LC; HDMSE; higher order structure; Host cell proteins; hydrogen deuterium exchange; ion mobility spectrometry; N linked glycans; QTof; RapiFluor MS; UPLC

Indexed keywords

GLYCAN; INFLIXIMAB; N GLYCOLOYLNEURAMINIC ACID; BIOSIMILAR AGENT; N-GLYCOLYLNEURAMINIC ACID; NEURAMINIC ACID DERIVATIVE; POLYSACCHARIDE;

AMINO ACID SEQUENCE; COMPLEMENTARITY DETERMINING REGION; DEUTERIUM HYDROGEN EXCHANGE; FLOW RATE; FUCOSYLATION; HOST CELL; HYDROGEN BOND; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHYSICAL CHEMISTRY; PROTEIN ANALYSIS; PROTEIN PURIFICATION; SEQUENCE HOMOLOGY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; CHEMISTRY; EVALUATION STUDY; HUMAN; PROCEDURES;

AMINO ACID SEQUENCE; BIOSIMILAR PHARMACEUTICALS; CHROMATOGRAPHY, LIQUID; DEUTERIUM EXCHANGE MEASUREMENT; HUMANS; INFLIXIMAB; MASS SPECTROMETRY; NEURAMINIC ACIDS; POLYSACCHARIDES;

EID: 84976600735     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2016.1193661     Document Type: Article

References (36)

1. J.M.Reichert. Antibodies to watch in 2016. MAbs 2016; 8:197-204; PMID:26651519; doi 10.1080/19420862.2015.1125583
2. A.Beck, E.Wagner-Rousset, D.Ayoub, A.Van Dorsselaer, S.Sanglier-Cianferani. Characterization of therapeutic antibodies and related products. Anal Chem 2013; 85:715-36; PMID:23134362; doi 10.1021/ac3032355
3. A.Beck. Biosimilar, biobetter and next generation therapeutic antibodies. MAbs 2011; 3:107-10; PMID:21285536; doi 10.4161/mabs.3.2.14785
4. Food and Drug Administration. Guidance for Industry. Scientific considerations in demonstrating biosimilarity to a reference product. 2015; http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
5. A.Beck, F.Debaene, H.Diemer, E.Wagner-Rousset, O.Colas, A.Van Dorsselaer, S.Cianferani. Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies. J Mass Spectrom 2015; 50:285-97; PMID:25800010; doi 10.1002/jms.3554
6. A.Beck, J.M.Reichert. Marketing approval of Mogamulizumab: A triumph for glyco-engineering. MAbs 2012; 4:419-25; PMID:22699226; doi 10.4161/mabs.20996
7. H.Liu, G.Ponniah, H.M.Zhang, C.Nowak, A.Neill, N.Gonzalez-Lopez, R.Patel, G.Cheng, A.Z.Kita, B.Andrien. In vitro and in vivo modifications of recombinant and human IgG antibodies. MAbs 2014; 6:1145-54; PMID:25517300; doi 10.4161/mabs.29883
8. Internation Conference on Harmonisation. Specifications: Test procedures and acceptance criteria for biotechnological/biological products Q6B. 1999; http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q6B/Step4/Q6B_Guideline.pdf
9. A.Beck, S.Sanglier-Cianferani, A.Van Dorsselaer. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal Chem 2012; 84:4637-46; PMID:22510259; doi 10.1021/ac3002885
10. International Conference on Harmonisation. Guidance on specifications: Test procedures and acceptance criteria for biotechnological/biological products. 1999; http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q6B/Step4/Q6B_Guideline.pdf
11. International Conference on Harmonisation. Guidance on Q5E comparability of biotechnological/biological products subject to changes in their manufacturing process. 2005; http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf
12. A.Beck, H.Diemer, D.Ayoub, F.Debaene, E.Wagner-Rousset, D.Carapito, A.Van Dorsselaer, S.Sanglier-Cianférani. Analytical characterization of biosimilar antibodies and Fc-fusion proteins. Trends Anal Chem 2013; 48:14; doi 10.1016/j.trac.2013.02.014
13. H.Xie, A.Chakraborty, J.Ahn, Y.Q.Yu, D.P.Dakshinamoorthy, M.Gilar, W.Chen, S.J.Skilton, J.R.Mazzeo. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. MAbs 2010; 2:379-94; PMID:20458189; doi 10.4161/mabs.11986
14. A.Beck, J.M.Reichert. Approval of the first biosimilar antibodies in Europe: A major landmark for the biopharmaceutical industry. MAbs 2013; 5:621-3; PMID:23924791; doi 10.4161/mabs.25864
15. H.Schellekens, E.Lietzan, F.Faccin, J.Venema. Biosimilar monoclonal antibodies: The scientific basis for extrapolation. Expert Opin Biol Ther 2015; 15:1633-46; PMID:26365396; doi 10.1517/14712598.2015.1083552
16. S.K.Jung, K.H.Lee, J.W.Jeon, J.W.Lee, B.O.Kwon, Y.J.Kim, J.S.Bae, D.I.Kim, S.Y.Lee, S.J.Chang. Physicochemical characterization of Remsima. MAbs 2014; 6:1163-77; PMID:25517302; doi 10.4161/mabs.32221
17. M.A.Lauber, Y.Q.Yu, D.W.Brousmiche, Z.Hua, S.M.Koza, P.Magnelli, E.Guthrie, C.H.Taron, K.J.Fountain. Rapid preparation of released N-glycans for HILIC analysis using a labeling reagent that facilitates sensitive fluorescence and ESI-MS detection. Anal Chem 2015; 87:5401-9; PMID:25927596; doi 10.1021/acs.analchem.5b00758
18. M.Satoh, S.Iida, K.Shitara. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther 2006; 6:1161-73; PMID:17049014; doi 10.1517/14712598.6.11.1161
19. D.Houde, S.A.Berkowitz, J.R.Engen. The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies. J Pharm Sci 2011; 100:2071-86; PMID:21491437; doi 10.1002/jps.22432
20. D.Tsuchida, K.Yamazaki, S.Akashi. Comprehensive characterization of relationship between higher-order structure and FcRn Binding affinity of stress-exposed monoclonal antibodies. Pharm Res 2016; 33:994-1002; PMID:26694753; doi 10.1007/s11095-015-1845-5
21. D.Houde, J.Arndt, W.Domeier, S.Berkowitz, J.R.Engen. Characterization of IgG1 conformation and conformational dynamics by hydrogen/deuterium exchange mass spectrometry. Anal Chem 2009; 81:2644-51; PMID:19265386; doi 10.1021/ac802575y
22. J.Fang, J.Richardson, Z.Du, Z.Zhang. Effect of Fc-glycan structure on the conformational stability of IgG revealed by hydrogen/deuterium exchange and limited proteolysis. Biochemistry 2016; 55:860-8; PMID:26812426; doi 10.1021/acs.biochem.5b01323
23. H.K.Khor, M.E.Jacoby, T.C.Squier, G.C.Chu, D.Chelius. Identification of methionine sulfoxide diastereomers in immunoglobulin gamma antibodies using methionine sulfoxide reductase enzymes. MAbs 2010; 2:299-308; PMID:20404551; doi 10.4161/mabs.2.3.11755
24. J.C.Silva, M.V.Gorenstein, G.Z.Li, J.P.Vissers, S.J.Geromanos. Absolute quantification of proteins by LCMSE: A virtue of parallel MS acquisition. Mol Cell Proteomics 2006; 5:144-56; PMID:16219938; doi 10.1074/mcp.M500230-MCP200
25. Y.Chernajovsky, A.Nissim (Eds.). Therapeutic Antibodies. BerlinHeidelberg: Springer-Verlag Berlin Heidelberg; 2008
26. T.Igawa, H.Tsunoda, T.Kuramochi, Z.Sampei, S.Ishii, K.Hattori. Engineering the variable region of therapeutic IgG antibodies. MAbs 2011; 3:243-252; PMID:21406966; doi 10.4161/mabs.3.3.15234
27. J.Fang, P.Nevin, V.Kairys, C.Venclovas, J.R.Engen, P.J.Beuning. Conformational analysis of processivity clamps in solution demonstrates that tertiary structure does not correlate with protein dynamics. Structure 2014; 22:572-81; PMID:24613485; doi 10.1016/j.str.2014.02.001
28. X.Wang, T.K.Das, S.K.Singh, S.Kumar. Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies. MAbs 2009; 1:254-67; PMID:20065649; doi 10.4161/mabs.1.3.8035
29. C.E.Doneanu, M.Anderson, B.J.Williams, M.A.Lauber, A.Chakraborty, W.Chen. Enhanced detection of low-abundance host cell protein impurities in high-purity monoclonal antibodies down to 1 ppm using ion mobility mass spectrometry coupled with multidimensional liquid chromatography. Anal Chem 2015; 87:10283-91; PMID:26266576; doi 10.1021/acs.analchem.5b02103
30. U.Distler, J.Kuharev, P.Navarro, Y.Levin, H.Schild, S.Tenzer. Drift time-specific collision energies enable deep-coverage data-independent acquisition proteomics. Nat Methods 2014; 11:167-70; PMID:24336358; doi 10.1038/nmeth.2767
31. U.Distler, J.Kuharev, P.Navarro, S.Tenzer. Label-free quantification in ion mobility-enhanced data-independent acquisition proteomics. Nat Protoc 2016; 11:795-812; PMID:27010757; doi 10.1038/nprot.2016.042
32. J.C.Silva, R.Denny, C.Dorschel, M.V.Gorenstein, G.Z.Li, K.Richardson, D.Wall, S.J.Geromanos. Simultaneous qualitative and quantitative analysis of the Escherichia coli proteome: A sweet tale. Mol Cell Proteomics 2006; 5:589-607; PMID:16399765; doi 10.1074/mcp.M500321-MCP200
33. J.Ahn, M.C.Jung, K.Wyndham, Y.Q.Yu, J.R.Engen. Pepsin immobilized on high-strength hybrid particles for continuous flow online digestion at 10,000 psi. Anal Chem 2012; 84:7256-62; PMID:22856522; doi 10.1021/ac301749h
34. T.E.Wales, J.R.Engen. Hydrogen exchange mass spectrometry for the analysis of protein dynamics. Mass Spectrom Rev 2006; 25:158-70; PMID:16208684; doi 10.1002/mas.20064
35. J.Fang, K.D.Rand, P.J.Beuning, J.R.Engen. False EX1 signatures caused by sample carryover during HX MS analyses. Int J Mass Spectrom 2011; 302:19-25; PMID:21643454; doi 10.1016/j.ijms.2010.06.039
36. S.J.Geromanos, C.Hughes, S.Ciavarini, J.P.Vissers, J.I.Langridge. Using ion purity scores for enhancing quantitative accuracy and precision in complex proteomics samples. Anal Bioanal Chem 2012; 404:1127-39; PMID:22811061; doi 10.1007/s00216-012-6197-y